Abstract
Survivin, a member of the IAP family is an attractive target for cancer treatment due to its over expression in most cancers and low or no expression in most differentiated adult tissues. Survivin expression is a poor prognostic marker in a number of cancers. Clinical trials are currently underway evaluating anti-sense oligonucleotides against Survivin, immunotherapy using Survivin primed dentritic cells and peptide mimics that block interaction of Survivin with Hsp90 resulting in loss of Survivin protein stability. Additional approaches using ribozymes against Survivin mRNA, or dominant-negative cDNA to block Survivin function are in pre-clinical stages. Like many genes, Survivin is alternately spliced and a number of new splice variants have recently been identified. Expression of some of these splice variants correlates with loss of steroid receptors as well as the tumor suppressor p53, in some cancers, suggesting that like wild-type Survivin, at least some of these splice variants may also have prognostic relevance. This review will focus on the current understanding of the function of Survivin splice variants and their expression and sub-cellular localization in normal and neoplastic tissues as well as critically evaluating the potential toxicity of the Survivin directed therapies and their predicted effect on the alternatively spliced Survivin isoforms. Supported by grants HL69669 and HL79654 to L.M.P from the National Institutes of Health.
Keywords: Survivin, splice variant, cancer expression, targeted therapy
Current Drug Discovery Technologies
Title: Alternative Splice Variants of Survivin as Potential Targets in Cancer
Volume: 4 Issue: 3
Author(s): Janardhan Sampath, Louis M. Pelus, Janardhan Sampath and Louis M. Pelus
Affiliation:
Keywords: Survivin, splice variant, cancer expression, targeted therapy
Abstract: Survivin, a member of the IAP family is an attractive target for cancer treatment due to its over expression in most cancers and low or no expression in most differentiated adult tissues. Survivin expression is a poor prognostic marker in a number of cancers. Clinical trials are currently underway evaluating anti-sense oligonucleotides against Survivin, immunotherapy using Survivin primed dentritic cells and peptide mimics that block interaction of Survivin with Hsp90 resulting in loss of Survivin protein stability. Additional approaches using ribozymes against Survivin mRNA, or dominant-negative cDNA to block Survivin function are in pre-clinical stages. Like many genes, Survivin is alternately spliced and a number of new splice variants have recently been identified. Expression of some of these splice variants correlates with loss of steroid receptors as well as the tumor suppressor p53, in some cancers, suggesting that like wild-type Survivin, at least some of these splice variants may also have prognostic relevance. This review will focus on the current understanding of the function of Survivin splice variants and their expression and sub-cellular localization in normal and neoplastic tissues as well as critically evaluating the potential toxicity of the Survivin directed therapies and their predicted effect on the alternatively spliced Survivin isoforms. Supported by grants HL69669 and HL79654 to L.M.P from the National Institutes of Health.
Export Options
About this article
Cite this article as:
Sampath Janardhan, Pelus M. Louis, Sampath Janardhan and Pelus M. Louis, Alternative Splice Variants of Survivin as Potential Targets in Cancer, Current Drug Discovery Technologies 2007; 4 (3) . https://dx.doi.org/10.2174/157016307782109652
DOI https://dx.doi.org/10.2174/157016307782109652 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Current Drug Safety Natural Products and Cancer Stem Cells
Current Pharmaceutical Design Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine Anticancer Properties of Asian Water Monitor Lizard (Varanus salvator), Python (Malayopython reticulatus) and Tortoise (Cuora kamaroma amboinensis)
Anti-Cancer Agents in Medicinal Chemistry Cytokines and Hormones in the Regulation of Hypoxia Inducible Factor-1α (HIF-1α)
Cardiovascular & Hematological Agents in Medicinal Chemistry Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Mucoadhesive Polymeric Platform for Drug Delivery; A Comprehensive Review
Current Drug Delivery Pediatric Differentiated Thyroid Cancer: When to Perform Conservative and Radical Surgery
Current Pediatric Reviews Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Artepillin C Induces Selective Oxidative Stress and Inhibits Migration and Invasion in a Comprehensive Panel of Human Cervical Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Searching for Novel Cancer Chemopreventive Plants and their Products:The Genus Zanthoxylum
Current Drug Targets Anticancer Effect of Amygdalin (Vitamin B-17) on Hepatocellular Carcinoma Cell Line (HepG2) in the Presence and Absence of Zinc
Anti-Cancer Agents in Medicinal Chemistry Ectopic Thyroid Gland: Description of a Case and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Versatile Synthesis of Organic Compounds Derived from Ascorbic Acid
Current Organocatalysis APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Nitric Oxide Regulation of Permeability in Human Cervical and Vaginal Epithelial Cells and in Human Endothelial Cells
Current Pharmaceutical Design HPV-Specific Immunotherapy: Key Role for Immunomodulators
Anti-Cancer Agents in Medicinal Chemistry Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy